Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,444 across all filing types
Latest filing 2014-12-15 Director's Dealing
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Change of Director's Interest Notice (PH) 2 pages 141.3KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including number of shares held before and after the change, nature of the change, and dates. This is a formal notification of a director's personal share transactions. The document is not a financial report, earnings release, or management discussion, but a regulatory disclosure of insider trading activity by a director. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is about 4,036 characters, consistent with a detailed insider transaction notice. Therefore, the correct classification is DIRS.
2014-12-15 English
Ceasing to be a substantial holder 1 page 62.1KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 605 Notice of ceasing to be a substantial holder under the Corporations Act 2001 Section 671B. It details changes in relevant interests and association related to substantial shareholding in Imugene Limited. This type of filing is a notification of changes in significant share ownership levels, which corresponds to the category Major Shareholding Notification (MRQ). The document length is short and focused solely on shareholding changes, not financial results or management information.
2014-12-15 English
Change in substantial holding 2 pages 318.7KB
Major Shareholding Notification Classification · 95% confidence The document contains tables showing changes in voting power and shareholdings, including details of a purchase plan and number of shares affected. The content focuses on changes in significant share ownership levels and voting power percentages. There is no indication of financial statements, management discussion, or regulatory certifications. The document length is short (910 characters), and the content aligns with notifications about major shareholding changes rather than a full report or announcement of a report. Therefore, the document fits best under Major Shareholding Notification (MRQ).
2014-12-15 English
Ceasing to be a substantial holder 1 page 695.9KB
Regulatory Filings
2014-12-15 English
Ceasing to be a substantial holder 1 page 835.4KB
Regulatory Filings
2014-12-15 English
Appendix 3B 13 pages 344.7KB
Capital/Financing Update Classification · 100% confidence The document is an Appendix 3B form, which is a standard Australian Securities Exchange (ASX) announcement used to notify the market of a new issue of securities, application for quotation of additional securities, and related agreements. It details the class and number of securities issued, issue price, purpose of the issue, shareholder approvals, and quotation agreements. The document does not contain financial statements or detailed financial performance data but rather focuses on capital raising activities and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed information about the securities issuance, consistent with a capital raising announcement rather than a brief notice or regulatory filing.
2014-12-14 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.